Table 3 Comparison of patients based on days of RDV therapy

Total

9

32

-

Males - n (%)

7 (78)

19 (59)

0.445

Weight (kg) - median ± IQR (range)

36.0 ± 42.5

(3.2–70.0)

67.5 ± 45.3

(4.0–130)

0.022

Age (years) - median ± IQR (range)

11.6 ± 13.1

(0.02–17.5)

12.8 ± 4.4

(0.2–17.1)

0.415

Hospitalization (days) - median ± IQR (range)

20.5 ± 24

(10–42)

10 ± 13

(2–63)

0.034

 PICU admission - n (%)

 PICU admission (days)

6 (67)

22 ± 7.3

(15–24)

7 (22)

7 ± 9

(4–15)

0.018

0.010

Comorbidities - n (%)

 Obesity

 Neurological disorder

 Primary or secondary immunodeficiency

 Pulmonary or thoracic condition

 Congenital disorder

 Other

6 (67)

0 (0)

2 (22)

2 (22)

0 (0)

0 (0)

0 (0)

27 (84)

9 (28)

5 (16)

5 (16)

2 (6)

4 (13)

3 (9)

0.342

0.167

0.637

0.637

1.000

0.559

1.000

Concomitant therapies - n (%)

2 (25)

8 (30)

1.000

Reported contact with

SARS-CoV-2 infected (%)

6 (67)

15 (47)

0.454

Symptoms - n (%)

 Fever

  Temperature (°C, max value)

  - mean ± SD (range)

8 (89)

39.1 ± 1.0

(38.0–40.8)

30 (94)

38.9 ± 0.5

(37.5–40.0)

0.535

0.317

 Cough

 Dyspnea

 Rhinorrhea

 Sore throat

 Chest pain

 Diarrhea

 Abdominal pain

 Vomiting

 Fatigue

 Anorexia

 Headache

 Joint/muscle pain

 Dysgeusia/anosmia

 Hypotonia

 Rash

 Seizures

 Conjunctivitis

6 (67)

7 (78)

5 (56)

0 (0)

0 (0)

3 (38)

2 (22)

2 (22)

0 (0)

2 (20)

0 (0)

0 (0)

0 (0)

0 (0)

1 (11)

0 (0)

0 (0)

25 (78)

22 (69)

4 (13)

8 (25)

5 (16)

4 (13)

3 (9)

3 (9)

5 (16)

2 (7)

3 (9)

3 (9)

2 (6)

1 (3)

1 (3)

1 (3)

0 (0)

0.662

0.702

0.014

0.164

0.563

0.128

0.299

0.299

0.568

0.213

1.000

1.000

1.000

1.000

0.395

1.000

-

Complications - n (%)

 Pneumoniae

  Viral

  Bacterial

  Mixed

 Acute respiratory failure

 ARDS

 MIS-C

7 (100)

9 (100)

3 (43)

0 (0)

4 (57)

7 (78)

5 (56)

2 (22)

20 (77)

31 (97)

18 (69)

1 (4)

6 (23)

16 (50)

2 (7)

1 (3)

0.301

1.000

0.337

1.000

0.161

0.254

0.003

0.116

Administration of O2 - n (%)

 Mask/nasal cannulae

 High-flow nasal cannulae - HFNC

 Non-invasive ventilation - NIV

 Mechanical ventilation

 Extra-Corporeal Membrane

 Oxygenation - ECMO

5 (56)

2 (29)

3 (38)

4 (44)

0 (0)

21 (66)

9 (38)

7 (22)

1 (3)

0 (0)

0.701

1.000

0.388

0.007

-

Total duration of O2

administration/ventilation (days)**

5 ± 15.5

(0–24)

2.5 ± 6

(0–19)

0.392

Clinical outcome

 Recovery without sequelae - n (%)

 Death - n (%)

5 (71)

0 (0)

26 (96)

1 (3)

0.101

1.000

Laboratory workup

 Leukocytosis - n (%)

 Leukopenia - n (%)

 Increased PCR - n (%)

 Increased PCT - n (%)

 Bacterial coinfection - n (%)

2 (22)

7 (78)

6 (67)

3 (33)

4 (67)

6 (17)

14 (61)

21 (68)

2 (7)

24 (86)

0.653

0.441

1.000

0.070

0.281

RDV administration

 Time from onset to RDV administration (days)**

8 ± 2

(5–11)

5.5 ± 3

(0–15)

0.069

 Time from pneumonia to RDV administration (days)**

3 ± 2

(2–8)

1 ± 2

(0–7)

0.010

Safety evaluation of RDV administration

 AST (U/L, max value) - median ± IQR (range)

43 ± 26

(22–62)

43 ± 72

(19–164)

0.584

 ALT (U/L, max value) - median ± IQR (range)

25 ± 30

(21–58)

66 ± 123

(6–350)

0.057

 Creatinine (mg/dl, max value) - median ± IQR (range)

0.4 ± 0.4

(0.2–0.8)

0.6 ± 0.3

(0.1–0.9)

0.259

 Ipertransaminasemia - n (%)

 Bradicardia - n (%)

 Rash - n (%)

0 (0)

0 (0)

0 (0)

15 (65)

2 (6)

3 (9)

0.028

1.000

1.000

Antibiotic therapy

 Macrolides - n (%)

  Duration (days) - median ± IQR (range)

3 (33)

-

-

6 (22)

6.5 ± 8

(0–9)

0.660

0.480

 Other than macrolides - n (%)

  Duration (days) - median ± IQR (range)

7 (78)

9 ± 16

(5–28)

22 (69)

9.5 ± 9

(4–23)

0.702

0.836

Corticosteroid therapy - n (%)

 Duration (days) - median ± IQR (range)

7 (78)

11 ± 24

(4–36)

27 (84)

9 ± 7

(3–36)

0.637

0.784

Heparin - n (%)

 Duration (days) - median ± IQR (range)

3 (43)

24 ± 13

(8–28)

9 (38)

8.5 ± 11

(2–58)

1.000

0.940